FDA clears BioPhotas light therapy device for pain management and certain skin conditions

7 January 2013 (Last Updated January 7th, 2013 18:30)

The US Food and Drug Administration (FDA) has cleared BioPhotas' patented biophotonic medical device, designed to treat acne, muscle and joint pain, muscle and joint stiffness, muscle spasm, arthritis and compromised local blood circulation.

The US Food and Drug Administration (FDA) has cleared BioPhotas' patented biophotonic medical device, designed to treat acne, muscle and joint pain, muscle and joint stiffness, muscle spasm, arthritis and compromised local blood circulation.

Designed for use in home and professional medical settings, Celluma, a light therapy device, utilises three distinct wavelengths of light energy modulated with proprietary electronic algorithms to re-energise cellular functions and create a natural healing response.

Funded by NASA and DARPA, the research using biophotonic therapy or light emitting diodes has proven to up-regulate cellular function and restore the body's natural ability to heal itself in recent clinical trials.

"Designed for use in home and professional medical settings, Celluma, a light therapy device, utilises three distinct wavelengths of light energy modulated with proprietary electronic algorithms to re-energise cellular functions and create a natural healing response."

The device also includes a flexible design that molds to the body to allow the light to be absorbed more effectively leading to higher efficacy and more predictable outcomes, according to the company.

BioPhotas president and chief executive officer Patrick Johnson said with the development of Celluma, the company has accomplished its goal with a product that is proprietary in design and novel in clinical application for pain management and certain skin conditions.

"BioPhotas' vision is to address the rapidly growing market opportunity in global healthcare and wellness with the proven science of biophotonics and LED technology featured in the Celluma to provide effective, affordable and predictable solutions for medical practitioners and consumers alike," Johnson said.

"The Celluma will give consumers and medical professionals affordable access to a powerful clinical technology that could otherwise cost 5 to 20 times more, particularly when compared to cold lasers used to treat the same conditions."